Mr. Pejic leads the Greenblum & Bernstein litigation/trial practice group, is a member of the firm’s start-up/acquisition group, and serves on the firm’s management committee.  Prior to joining G&B in 1999, Mr. Pejic clerked for a U.S. District Court Judge, and completed a mini-pupilage at Grey’s Inn, London, England.  Mr. Pejic litigates a wide spectrum of technologies on behalf of numerous foreign companies in disputes before the U.S. Federal District and Appellate Courts and in contested proceedings before the U.S. Patent and Trademark Office, advises in merger/acquisition transactions, and counsels clients on intellectual property matters including patent, licensing and monetization strategies.  Mr. Pejic speaks on and has published articles on these issues as well U.S. litigation practice and strategies, and currently serves as the Secretary of the U.S. FICPI section.    

Mr. Pejic’s primary focus is pharmaceutical/bio-tech, including Hatch-Waxman ANDA litigations, and high-tech technologies.  He has represented both innovator and generic drug companies in litigations, including serving as lead trial and appellate counsel for generic manufacturers in several “blockbuster” drug litigations, as well as patentees and accused infringers in various other technologies, including medical devices.  Mr. Pejic additionally has served as lead IP counsel in due diligence and negotiations for multiple transactions to acquire/sell patents, business divisions and products as well in/out licensing of patent portfolios in the pharma/bio fields.  Mr. Pejic holds a B.S. in Chemical Engineering, a Juris Doctorate and an LL.M. in International and Comparative Law with a focus on Intellectual Property from Georgetown Law Center.